LYAR and Schnyder corneal dystrophy: Our results indicate that LYAR binds to the DNA region corresponding to 5′UTR of the γ-globin gene, and participates in silencing human fetal globin gene expression, suggesting that LYAR may represent a new therapeutic target for treatment of β-thalassemia and SCD.